SOURCE: Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc.

March 26, 2014 11:50 ET

Therapeutic Solutions International, Inc. Announces New Division

OCEANSIDE, CA--(Marketwired - Mar 26, 2014) -  Therapeutic Solutions International, Inc. (OTCQB: TSOI) announced today the creation of a new supplement division focusing on Direct to Consumer sales.

Tim Dixon, Chief Executive Officer, stated, "We are launching this Division online with an initial five products. Three of our initial products are T-Rx™, a product that naturally increases Testosterone; Vital™, a product for the active female; and Noxon 240g™, a pre-workout Nitric Oxide (NO) product. Please visit our website www.ordertsoi.com for complete descriptions and additional products."

According to an article in Forbes Magazine "one of the fastest growing industries in the world is the nutritional supplement group, or more broadly known as Vitamins, Minerals and Supplements, or VMS. Producing about $32 billion in revenue for just nutritional supplements alone in 2012, it is projected to double that by topping $60 billion in 2021 according to the Nutritional Business Journal."

Mr. Dixon further stated, "The Company will be looking to add additional products in the future. We are very excited to enter into this growing industry. All of our products will be manufactured in the United States in Good Manufacturing Practice (GMP) facilities."

About Therapeutic Solutions International, Inc. Supplement Division

The Company's corporate website is www.therapeuticsolutionsint.com. Our new products can be ordered on www.ordertsoi.com. The Supplement products sold have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at www.sec.gov.

Contact Information

  • Contact Information
    For more information please contact:
    Therapeutic Solutions International, Inc.
    ir@tsoimail.com